212 related articles for article (PubMed ID: 9169735)
1. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus.
Ji Y; Carlson B; Kondagunta A; Cleary PP
Infect Immun; 1997 Jun; 65(6):2080-7. PubMed ID: 9169735
[TBL] [Abstract][Full Text] [Related]
2. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils.
Park HS; Cleary PP
Infect Immun; 2005 Dec; 73(12):7878-86. PubMed ID: 16299278
[TBL] [Abstract][Full Text] [Related]
3. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice.
Cleary PP; Matsuka YV; Huynh T; Lam H; Olmsted SB
Vaccine; 2004 Oct; 22(31-32):4332-41. PubMed ID: 15474726
[TBL] [Abstract][Full Text] [Related]
4. C5a peptidase alters clearance and trafficking of group A streptococci by infected mice.
Ji Y; McLandsborough L; Kondagunta A; Cleary PP
Infect Immun; 1996 Feb; 64(2):503-10. PubMed ID: 8550199
[TBL] [Abstract][Full Text] [Related]
5. Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development.
Shet A; Kaplan EL; Johnson DR; Cleary PP
J Infect Dis; 2003 Sep; 188(6):809-17. PubMed ID: 12964111
[TBL] [Abstract][Full Text] [Related]
6. Impact of M49, Mrp, Enn, and C5a peptidase proteins on colonization of the mouse oral mucosa by Streptococcus pyogenes.
Ji Y; Schnitzler N; DeMaster E; Cleary P
Infect Immun; 1998 Nov; 66(11):5399-405. PubMed ID: 9784550
[TBL] [Abstract][Full Text] [Related]
7. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.
Wozniak A; Scioscia N; García PC; Dale JB; Paillavil BA; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM
Microbiol Immunol; 2018 Jun; 62(6):395-404. PubMed ID: 29704396
[TBL] [Abstract][Full Text] [Related]
8. Human immunogenicity studies on group A streptococcal C5a peptidase (SCPA) as a potential vaccine against group A streptococcal infections.
Shet A; Kaplan E; Johnson D; Cleary PP
Indian J Med Res; 2004 May; 119 Suppl():95-8. PubMed ID: 15232171
[TBL] [Abstract][Full Text] [Related]
9. Conservation of the C5a peptidase genes in group A and B streptococci.
Chmouryguina I; Suvorov A; Ferrieri P; Cleary PP
Infect Immun; 1996 Jul; 64(7):2387-90. PubMed ID: 8698456
[TBL] [Abstract][Full Text] [Related]
10. Protective immunization in mice against group B streptococci using encapsulated C5a peptidase.
Santillan DA; Andracki ME; Hunter SK
Am J Obstet Gynecol; 2008 Jan; 198(1):114.e1-6. PubMed ID: 17905172
[TBL] [Abstract][Full Text] [Related]
11. In vivo Streptococcus pyogenes C5a peptidase activity: analysis using transposon- and nitrosoguanidine-induced mutants.
O'Connor SP; Cleary PP
J Infect Dis; 1987 Sep; 156(3):495-504. PubMed ID: 3039012
[TBL] [Abstract][Full Text] [Related]
12. Multi-functional mechanisms of immune evasion by the streptococcal complement inhibitor C5a peptidase.
Lynskey NN; Reglinski M; Calay D; Siggins MK; Mason JC; Botto M; Sriskandan S
PLoS Pathog; 2017 Aug; 13(8):e1006493. PubMed ID: 28806402
[TBL] [Abstract][Full Text] [Related]
13. Active and passive immunizations with the streptococcal esterase Sse protect mice against subcutaneous infection with group A streptococci.
Liu M; Zhu H; Zhang J; Lei B
Infect Immun; 2007 Jul; 75(7):3651-7. PubMed ID: 17502395
[TBL] [Abstract][Full Text] [Related]
14. Co-Activation of Th17 and Antibody Responses Provides Efficient Protection against Mucosal Infection by Group A Streptococcus.
Chen X; Li N; Bi S; Wang X; Wang B
PLoS One; 2016; 11(12):e0168861. PubMed ID: 28030629
[TBL] [Abstract][Full Text] [Related]
15. An Experimental Group A
Rivera-Hernandez T; Carnathan DG; Jones S; Cork AJ; Davies MR; Moyle PM; Toth I; Batzloff MR; McCarthy J; Nizet V; Goldblatt D; Silvestri G; Walker MJ
mBio; 2019 Apr; 10(2):. PubMed ID: 31040243
[TBL] [Abstract][Full Text] [Related]
16. [Recombinant fragments of conservative proteins of group B streptococci as a basis of specific vaccine].
Suvorov AN; Grabovskaia KB; Leont'eva GF; Meringova LF; Koroleva IN; Duplik NV; Totolian AA
Zh Mikrobiol Epidemiol Immunobiol; 2010; (2):44-50. PubMed ID: 20465000
[TBL] [Abstract][Full Text] [Related]
17. Sortase A induces Th17-mediated and antibody-independent immunity to heterologous serotypes of group A streptococci.
Fan X; Wang X; Li N; Cui H; Hou B; Gao B; Cleary PP; Wang B
PLoS One; 2014; 9(9):e107638. PubMed ID: 25232948
[TBL] [Abstract][Full Text] [Related]
18. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
Mannam P; Jones KF; Geller BL
Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
[TBL] [Abstract][Full Text] [Related]
19. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.
Hall MA; Stroop SD; Hu MC; Walls MA; Reddish MA; Burt DS; Lowell GH; Dale JB
Infect Immun; 2004 May; 72(5):2507-12. PubMed ID: 15102757
[TBL] [Abstract][Full Text] [Related]
20. The human antibody response to streptococcal C5a peptidase.
O'Connor SP; Darip D; Fraley K; Nelson CM; Kaplan EL; Cleary PP
J Infect Dis; 1991 Jan; 163(1):109-16. PubMed ID: 1984457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
